As mass COVID-19 vaccination drives continue, new data from Finaria.it shows vaccine developers Biontech-Pfizer (NASDAQ: BNTX, NYSE: PFE) and Moderna (NASDAQ: MRNA) earn 14.7 billion in revenue from revenue It has been revealed that it is set to a dollar bank. Coronavirus vaccines by 2023.
The Pfizer BioNTech candidate made the headline when the UK’s Drugs and Health Regulatory Authority (MHRA) approved JAB in early December to make it the first vaccine approved for public use. So far, the joint effort by American Pfizer and Germany’s BionTech is targeting 40 million doses from the UK government and is expected to earn $3.1 billion in sales in 2021.
However, this figure is expected to fall below $1.4 billion in 2022 and continue to drip over the next few years. The most important drawback of the Biontech-Pfizer vaccine is that it requires ultra-cooled storage at temperatures as low as -70°C, which already poses serious logistical challenges for the UK and many other countries.
As we hope to see mass inoculations in 2023 enter the final stage, sales of the BionTech-Pfizer Covid-19 vaccine are projected to generate just $914 million, almost 3.5 times that of 2021. Alternatives.
Moderna already enjoys global interest in vaccines. The vaccine boasts 94.1% effectiveness based on last year’s Phase III clinical trial, and has already booked a request for 17 million doses from the UK government. Unlike the BionTech -Pfizer vaccine, Moderna must be stored in a standard refrigerator temperature between -25°C and -15°C. The American pharmaceutical company behind it is expected to generate $3.5 billion in revenue in 2021 alone. It’s $400 million more than its competitors.
Statistics already approved in the UK, the US, the EU, Canada and Israel show that the Moderna vaccine can generate annual sales revenue of $2.9 billion over the next two years.
However, it is the much-appreciated collaboration between the University of Oxford and Zeneca in the UK that leads the pack in terms of total order doses. By the beginning of this year, around 3 billion doses had been pre-ordered by many countries around the world. This is the fact that so far, the cheapest vaccine to produce at around 3 pounds per dose is the cheapest, and what it does. There is no need to store it at ultra-low temperatures.
Also, still in Phase III of clinical trials, and without regulatory approval, the offer from American vaccine developer Novavax (NASDAQ: NVAX) is the second highest with around 1.3 billion orders worldwide .
Data shows that last week, rivals from Russia’s Gamaleya, Anglo-France Sanofi/GSK and Moderna continued to order 727, 712 and 441 million respectively. This shows that the BioNTech Pfizer vaccine, which hit the order dose, has already reached an ordered dose of 816 million.
